



**SURETERIC<sup>®</sup>**  
AQUEOUS ENTERIC COATING SYSTEM

Technical Data Sheet

Coating Application

## Effect of Dissolution Media pH on the Release of Aspirin from Sureteric<sup>®</sup> Coated Tablets

### Study Purpose:

To investigate the effect of enteric-coating weight gain, and dissolution media pH on the release of aspirin from delayed release tablets.

### Methods:

Aspirin tablets (325 mg) were coated in a 24" Accela-Cota with a 2.0% weight gain of Opadry<sup>®</sup> Y-1-7000 (subcoat), and a 10.0% weight gain of Sureteric YAE-6-18108. Samples were taken at theoretical Sureteric weight gains of 5.0, 7.5, and 10.0%. No topcoat was applied. Tablets at each weight gain were tested using the U.S.P. Method I for Delayed Release Aspirin Tablets. The acid phase of testing was conducted using 0.1N HCL. In addition to the standard 6.8 phosphate buffer required for drug release testing of aspirin, U.S.P. phosphate buffers at pH 5.8 and 7.5 were also used for testing.

The U.S.P. criteria for delayed release aspirin requires that not more than 10.0% aspirin is released in 0.1N HCL after 2 hours. The aspirin tablets are then transferred into the buffer phase where not less than 80.0% of the aspirin must be released within 90 minutes.

### Dissolution Results: Acid Phase


Weight Gain	Percent Aspirin Released IN 0.1N HCl		
	A	B	C
5.0	0.67	0.14	0.8
7.5	0.09	0.2	0.14
10.0	0.1	0.09	0.13

All tablet samples passed the acid phase of testing. A, B, and C designates samples which were then transferred to pH 5.8, 6.8, and 7.5 phosphate buffers.


### Buffer Phase Results

As shown in figures 1, 2 and 3, tablets coated with a 5.0, 7.5, or 10.0% weight gain of Sureteric met the drug release criteria in pH 6.8 as well as pH 7.5 buffer. Tablets of various weight gains, however, exhibited slow dissolution characteristics in buffer solution, pH 5.8.


**Figure 1. Drug Release from Aspirin Tablets with 5% Weight Gain**



**Figure 2. Drug Release from Aspirin Tablets with 7.5% Weight Gain**



**Figure 3. Drug Release from Aspirin Tablets with 10% Weight Gain**



## **Conclusion**

Aspirin tablets coated with as little as a 5.0% theoretical weight gain of Sureteric met drug release criteria for USP Delayed Release Aspirin Tablets. Increasing weight gains of Sureteric did not significantly slow the release of aspirin in 6.8 and 7.5 buffers.

Samples tested for drug release in pH 5.8 buffer failed, with the highest amount of aspirin release being 37.5% in 90 minutes for the 5.0% w.g. sample.

**World Headquarters**

Colorcon

415 Moyer Blvd., P.O. Box 24, West Point, PA 19486-0024

Tel: 215-699-7733 Fax: 215-661-2605 Web Site @<http://www.colorcon.com> E.mail: [modified\\_release@colorcon.com](mailto:modified_release@colorcon.com)

<b>Locations</b>	<b>Telephone</b>	<b>Facsimile</b>	<b>Locations</b>	<b>Telephone</b>	<b>Facsimile</b>
<i>United States</i>			<i>Asia/Pacific</i>		
Santa Ana, California	714-549-0631	714-549-4921	Singapore	65-6438-0318	65-6438-0178
Indianapolis, Indiana	317-545-6211	317-545-6218	Nishiyama, Japan	81-5-4465-2711	81-5-4465-2730
Humacao, Puerto Rico	787-852-3815	787-852-0030	Shanghai, China	86-21-5442-2222	86-21-5442-2229
<i>Europe</i>			Goa, India	91-832-288-3434	91-832-288-3440
Dartford, Kent, England	44-1322-293000	44-1322-627200	Seoul, Korea	82-2-2057-2713	82-2-2057-2179
Bougival, France	33-1-3082-1582	33-1-3082-7879	<i>Latin America</i>		
Idstein, Germany	49-6126-9961-0	49-6126-9961-11	Buenos Aires, Argentina	54-911-4552-1565	54-911-4552-3997
Gallarate, Italy	39-0331-776932	39-0331-776831	Cotia, Brasil	55-11-4612-4262	55-11-4612-3307
Budapest, Hungary	36-1-200-8000	36-1-200-8010	Bogota, Colombia	571-418-1202	571-418-1257
Barcelona, Spain	34-9-3589-3756	34-9-3589-3792	Santa Fe, Mexico	525-5-3000-5700	525-5-3000-5701
Istanbul, Turkey	90-216-465-0360	90-216-465-0361	Caracas, Venezuela	58-212-442-4819	58-212-442-8724

The information contained herein, to the best of our knowledge is true and accurate. Any recommendations or suggestions are made without warranty or guarantee, since the conditions of use are beyond our control. Any information contained herein is intended as a recommendation for use of our products so as not to infringe on any patent.

© Colorcon, 2006. The information contained in this document is proprietary to Colorcon and may not be used or disseminated inappropriately. Sureteric<sup>®</sup> and Opadry<sup>®</sup> are registered trademarks of BPSI Holdings Inc. [mr/sureteric/coating\\_with\\_sureterice/10.2006](http://mr/sureteric/coating_with_sureterice/10.2006), Rev 3

First published 04.1998. Revised 10.2006